MedTrace Logo

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

NCT01466387 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 552

Last updated 2014-03-11

Study results available
· View outcomes & findings →

Summary

This study compares the safety and immunogenicity profile of several travel vaccines given alone or concomitantly with MenACWY-CRM to healthy adults.

Conditions

  • Meningococcal Disease
  • Meningococcal Meningitis
  • Typhoid
  • Yellow Fever
  • Rabies
  • Japanese Encephalitis

Interventions

BIOLOGICAL

Typhoid Vi Polysaccharide Vaccine

One dose of typhoid Vi polysaccharide vaccine.

BIOLOGICAL

Yellow Fever Vaccine

One dose of yellow fever vaccine.

BIOLOGICAL

Japanese Encephalitis Vaccine

Two doses of Japanese Encephalitis Vaccine.

BIOLOGICAL

Rabies Vaccine

Three doses of Rabies vaccine.

BIOLOGICAL

MenACWY-CRM Vaccine

One dose of MenACWY-CRM vaccine.

Sponsors & Collaborators

  • Novartis Vaccines

    collaborator INDUSTRY

  • Novartis

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • Czechia
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01466387 on ClinicalTrials.gov